Co-Founder of VSEL(TM) Technology Joins NeoStem’s Scientific Advisory Board
(“NeoStem” or the “Company”), an international biopharmaceutical company with
operations in
appointed to its Scientific Advisory Board (“SAB”) Mariusz Ratajczak, M.D.,
Ph.D., a world renowned investigator in the field of adult stem cells and
co-inventor of the VSEL(TM) technology to which the Company has an exclusive
license from the
Dr. Ratajczak is the director of the Stem Cell Institute (“SCI”) at the
James Graham Brown Cancer Center at the
professor in the Department of Microbiology and Immunology at the same
university. As a thought leader in the field of adult stem cell biology, he
has published numerous books and more than 300 peer-reviewed publications and
is a frequent speaker at conferences worldwide.
Through the pioneering research work led by Dr. Ratajczak, his team
discovered a heterogeneous population of stem cells, in the bone marrow, with
properties similar to those of an embryonic stem cell, known as very small
embryonic-like stem cells. This ground breaking discovery opens the door for
the potential application of these special cells to provide positive benefits
associated with embryonic stem cells without certain of the potential negative
or controversial effects associated with embryonic stem cells. Combined with
NeoStem’s stem cell banking capabilities to collect, process and store very
small embryonic-like cells from individual donors, these special cells have
significant potential for autologous use in the future in a variety of
personalized medicine applications.
Prior to joining NeoStem’s SAB as a formal advisor, Dr. Ratajczak was
already collaborating with the Company through a sponsored research agreement
conducting further research relating to VSEL(TM) technology and its
potentially vast applications. Dr. Ratajczak’s team at the
Louisville
embryonic-like stem cells potentially have a prominent role in regenerative
medicine to repair degenerated, damaged or diseased tissue.
“NeoStem is a leader in pursuing innovative approaches to cell-based
therapeutics,” said Dr. Ratajczak. “I look forward to working with Dr.
Marasco and the rest of the Scientific Advisory Board to help the Company
advance the application of VSEL(TM) technology to fulfill our goal of its
playing an important role as a new generation of stem cell therapies and
diagnostics.”
Board, said, “We welcome Dr. Ratajczak’s important addition to the Company’s
Scientific Advisory Board and look forward to further leveraging his
significant research experience and leadership in the stem cell field. Dr.
Ratajczak is an internationally recognized expert in stem cell research, and
his discovery of very small embryonic-like stem cells has provided researchers
with a novel platform from which to accelerate progress in the rapidly
emerging field of regenerative medicine.”
In addition to collaborations with Dr. Ratajczak and other researchers,
the Company is working on its own to develop adult stem cell therapeutics and
diagnostic tools that leverage the VSEL(TM) technology know-how and is
developing other isolation methods for very small embryonic-like stem cells
and establishing a stem cell high-throughput analysis for personalized
screening.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies,
pursuit of anti-aging initiatives and building of a network of adult stem cell
collection centers in the U.S. and
to donate and store their own (autologous) stem cells for their personal use
in times of future medical need. The Company is also the licensee of various
stem cell technologies, including a worldwide exclusive license to VSEL(TM)
technology which uses very small embryonic-like stem cells, shown to have
several physical characteristics that are generally found in embryonic stem
cells, and is pursuing the licensing of other technologies for therapeutic use.
NeoStem’s majority-controlled Chinese pharmaceutical operation, Suzhou Erye,
manufactures and distributes generic antibiotics in
information, please visit: http://www.neostem.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management’s current expectations, as of the date of this
press release, and involve certain risks and uncertainties. Forward looking
statements include statements herein with respect to the application of
VSEL(TM) technology and success of developing stem cell therapeutics and
diagnostics for regenerative diseases, about which no assurances can be given.
The Company’s actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Factors that
could cause future results to materially differ from the recent results or
those projected in forward-looking statements include the “Risk Factors”
described in the Company’s Registration Statement on Form S-1 filed with the
Securities and Exchange Commission on as well as periodic filings made with
the Securities and Exchange Commission. The Company’s further development is
highly dependent on future medical and research developments and market
acceptance, which is outside its control.
For more information, please contact:
NeoStem, Inc.
Robin Smith, CEO
Phone: +1-212-584-4174
Email: rsmith@neostem.com
Web: http://www.neostem.com
CCG Investor Relations, Inc.
Lei Huang, Account Manager
Phone: +1-646-833-3417
Email: lei.huang@ccgir.com
Web: http://www.ccgirasia.com
Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
SOURCE NeoStem, Inc.